CNRS Confirms Lupuzor’sTM Effectiveness 28th January 2013 - 3:14 pm
ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, LupuzorTM has issued a press release confirming the effectiveness of the LupuzorTM peptide P140.
LupuzorTM is ImmuPharma’s lead compound and potential blockbuster drug for Lupus, a chronic autoimmune disease. LupuzorTM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial.
CNRS Press Release : Summary
A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller (see notes to Editors) at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immuno-suppressants. These results are published online in the Annals of the Rheumatic Diseases.